Dr. Saadvik Raghuram y retweeted
Hyderabad-based paediatrician @dr_sivaranjani has resigned from the Indian Academy of Paediatrics, citing a lack of institutional support after receiving legal notices from pharmaceutical companies over her remarks on oral rehydration products.
✍️@The_SidSingh
thehindu.com/news/cities/Hyd… -
Dr. Saadvik Raghuram y retweeted
Nitin Gadkari ji says "A new AI-driven toll system will capture photos of number plates & deduct toll amount directly from bank accounts".
So why can’t we use same technology to capture photos of potholes & deduct salaries of govt employees?
Accountability can't be one sided!
Dr. Saadvik Raghuram y retweeted
₹19,000 crore.
That is what Banks collected in last 3 years just for not maintaining ‘Minimum Account Balance.’
Not from the rich. Not from big borrowers.
From the poorest accounts in the system.
Their crime? They didn’t have enough money.
A farmer misses the minimum balance - Penalty.
A pensioner withdraws money for medicine - Penalty.
A daily wage worker falls short by a few hundred rupees - Penalty.
The poor keep money in banks for safety. Not to be quietly fined for being poor.
Financial inclusion should protect small savings, not punish small balances.
In Parliament today I proposed ending minimum balance penalties so the banking system stops charging people for their poverty.
Dr. Saadvik Raghuram y retweeted
🆕🗞️ A Vaccine💉for cancer🦀interception.
A preventative approach aiming to reduce cancer incidence by targeting precancers and early-stage cancers. For patients with Lynch syndrome. Out @NatureMedicine📰
Paradigm↩️intervene early✅
#Cancer @OncoAlert
nature.com/articles/s41591-0…
Dr. Saadvik Raghuram y retweeted
💉 GLP-1 works—but muscles decide the outcome.
🔬 A new meta-analysis (18 RCTs, ~3,800 participants) shows significant weight regain and worsening metabolic health after GLP-1 discontinuation
thelancet.com/journals/eclin…
Dr. Saadvik Raghuram y retweeted
What’s the point in releasing such photos of the Indigo CEO sitting with folded hands, when the truth is that it is the government that has buckled and rolled back the FDTL norms and has been unsuccessful in taking stringent action for disruption in the skies?
The culprit isn’t the airline but those who turned a blind eye to the market capture& allowed things to fester till this point
Dr. Saadvik Raghuram y retweeted
It’s time for #ASH25! Here is a📝 of 🔑studies from #CommunityOncologists perspective.
- #BRUINCLL313
- #WINDOW3
- #ALPINE
- #MajesTEC3
- #MRD in Myeloma
- #COBRA
- #AUGMENT101
- #GimemaALL2820
- #VAYHIT2
- #VERIFY
#mmsm #lymsm #leuksm #HemeTwitter @ASH_hematology
Dr. Saadvik Raghuram y retweeted
Durvalumab + FLOT—>✂️—>Durva now @FDAOncology ✅ for resectable GEJ/Gastric Ca based off #MATTERHORN study.
- ⭐️ Improved OS in all comers (HR: 0.78)
- Rate of✂️, # of FLOT, and AEs (Gr 3 & 4: 71%) similar in both arms.
#OncTwitter @OncoAlert @OncUpdates @YJanjigianMD 👏👏
5th Plenary #ASCO25: #MATTERHORN Ph III, Durvalumab + FLOT—>✂️—>Durva vs NeoAdj FLOT in resectable GEJ/Gastric Ca.
- 2yr EFS 67% vs 59% (HR: 0.71). Improvement regardless of PDL1
- 2yr OS 76% vs 70%. mOS NR
- Rate of✂️& number of FLOT similar in both arms
- D-FLOT new SoC!
Dr. Saadvik Raghuram y retweeted
PeriOP Enfortumab + Pembro in cis-ineligible MIBC followed by postOP EV + Pembro now @US_FDA ✅ based off #KEYNOTE905 #EV303 study:
- EFS At 2yrs: 74.7% vs. 39.4%
- EFS HR: 0.40
- OS at 2yrs: 79.7% vs. 63.1 (HR: 0.50)
#OncTwitter #MedTwitter
Dr. Saadvik Raghuram y retweeted
Practice-changing study in hematology!
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial
Out in @JCO_ASCO
ascopubs.org/doi/10.1200/JCO…
Dr. Saadvik Raghuram y retweeted
We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing.
oncodaily.com/insight/talect…
Dr. Saadvik Raghuram y retweeted
We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing.
oncodaily.com/science/afatin…
Dr. Saadvik Raghuram y retweeted
Secondary malignancy risk after testicular GCT treatment
21 trials, 88,863 pts, mFU: 12.5y
No ⬆️ risk with surgery alone
⬆️ risk with RT (1.66), chemo (1.65), or both (2.73)
💥Important to keep in mind when deciding treatment in stage 1
@JNCI_Now
academic.oup.com/jnci/advanc…
Dr. Saadvik Raghuram y retweeted
The more complex the Ayurvedic herbal product is, the higher chance that it can actually harm the consumer. Multiple herbal components are the biggest risk factor for herb-induced liver injury as per ours and others published scientific work. This product also contains well known liver damaging herbs, not one, but multiple.
Baidyanath Ayurvedic products were analysed by us years ago and they were all substandard, crazy adulterated and contaminated products. Here is a full link to the analysis: teapawt.org/theliverdr/status/1354….
We analysed these because some moron named Fit Tuber called these as "safer alternative" to "allopathic medicines," a claim we eventually proved wrong with objective evidence. These herbal drugs were far inferior from a clinical point of view and far superior from a danger point of view.
I am very worried about people who subject themselves to being guinea pigs for the Ayurveda industry. It's a gamble. Completely untested, unregulated complex herbal products that are flooding the market promoted as "supplements" and totally ignorant people consuming it without understanding the consequences, some of which may even result in severe organ damage or organ failure. And a government that has zero care for public health.
India is a crazy place for healthcare choices.
This quoted post is unavailable.
Dr. Saadvik Raghuram y retweeted
From what threshold of TNBC size is it ok to unleash the 5-drug KEYNOTE-522 neoadjuvant regimen?
👉2 cm
Though this is hardly a magical threshold form which tumors dramatically change
We need to do better with biomarkers for this important choice!!!
Dr. Saadvik Raghuram y retweeted
Optimal duration of endocrine treatment in different clinical situations:
Dr. Saadvik Raghuram y retweeted
What adjuvant treatment for TNBC with residual disease after KN522?
👉cape + pembro
Dr. Saadvik Raghuram y retweeted
Great news!!
T-DXd has demonstrated an OS benefit in second-line treatment of HER2-positive metastatic gastric cancer, as announced in the DESTINY-Gastric04 trial. Due to its efficacy, the study has been unblinded
daiichisankyo.us/press-relea…
Dr. Saadvik Raghuram y retweeted
As a doctor, let me tell you the worst health insurance.
A. Star Health
B. Niva
C. Manipal Cigna.
D. Care
(<65% claim paid)
All are absolute scums.
Choose public sector (>90% incurred claim paid ratio) or in private - go for HDFC/ICICI/Tata(~80% incurred claim paid ratio)





































